Global NuTide:121 Study Is Enrolling up to 828 Patients and Comparing Acelarin plus Cisplatin to Gemcitabine plus Cisplatin NuTide:121 Trials-in-Progress Poster Presented at ASCO-GI SAN FRANCISCO, Jan. 27, 2020 — NuCana plc (NCNA) announced that the first...
Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that it has begun dosing healthy volunteers in a Phase 1 clinical trial of CVL-936, an orally-administered and potential first-in-class...
Clinical Data Intended to be Used to Support Pediatric Label Expansion for IXINITY Approximately 1/3 of U.S. Hemophilia B Patients are Under Twelve Years of Age; Pediatric Approval Could Significantly Increase the Addressable Patient Population for IXINITY SEATTLE, WA...
CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the...
JoBurmester.com is delighted to announce the launch of the first in a series of online learning courses designed to make clinical research regulatory training as effective as possible. Written by Jo Burmester, a well known expert in Good Clinical Practice (GCP), this...
MELBOURNE, Australia–(Business Wire)–Regenerative medicine company Exopharm Limited (ASX:EX1) announces first dosing has occurred in the PLEXOVAL Phase I study using exosomes isolated from human platelets for wound healing, Exopharm’s first human clinical...
Email
Text